Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.

YH, Park; SA, Im; K, Park; J, Wen; KH, Lee; YL, Choi; WC, Lee; A, Min; V, Bonato; S, Park; S, Ram; DW, Lee; JY, Kim; SK, Lee; WW, Lee; J, Lee; M, Kim; HS, Kim; SL, Weinrich; HS, Ryu; TY, Kim; S, Dann; YJ, Kim; DR, Fernandez; J, Koh; S, Wang; SY, Park; S, Deng; E, Powell; RK, Ravi; J, Bienkowska; PA, Rejto; WY, Park; Z, Kan

doi:10.1186/s13073-023-01201-7

Public

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.

Shared by NobleBlocks on Jul 20, 2023 • 12:00 AM UTC

Authors:

Park YH

Im SA

Park K

Abstract

<h4>Background</h4>Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2- MBC); however, resistance is common and poorly understoo...

Subject

Drug resistance

Advanced breast cancer

Gene expression profiling

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!